TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 INTC
Intel
-- 23.600 GCL
GCL Global
-- 3.049 NBIS
NEBIUS
-- 44.490 
NEWS
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio (NASDAQ: GRI) presented positive preclinical data for its lead program GRI-0621 at the 22nd International Colloquium on Lung and Airway Fibrosis. The data demonstrated GRI-0621's ability to inhibit invariant Natural Killer T (iNKT) cell activity and reduce inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).
Key findings include:
Increased expression of pro-fibrotic factors in IPF patients
Increased IFN-γ producing NKT cells in IPF patients
GRI-0621 treatment improved inflammatory, fibrotic, and pathological features in a bleomycin model of pulmonary fibrosis
GRI Bio is currently conducting a Phase 2a biomarker study of GRI-0621 in IPF patients, with interim data expected in Q4 2024 and topline results in Q1 2025.
Key findings include:
Increased expression of pro-fibrotic factors in IPF patients
Increased IFN-γ producing NKT cells in IPF patients
GRI-0621 treatment improved inflammatory, fibrotic, and pathological features in a bleomycin model of pulmonary fibrosis
GRI Bio is currently conducting a Phase 2a biomarker study of GRI-0621 in IPF patients, with interim data expected in Q4 2024 and topline results in Q1 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8164
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call